In the heathcare version of "Where the Money Is", guest Brian Orelli joins regulars Michael Douglass and David Williamson to discuss the state of the healthcare sector.
In M&A news, Endo International has made an unsolicited bid to acquire Auxilium Pharmaceuticals (NASDAQ: AUXL) for $28.10 a share in cash and stock; Auxilium's management wasn't too happy with the offer and set up a poison pill to thwart the takeover.
A couple of Alzheimer's disease drugs made headlines this week. Eli Lilly (LLY 0.12%) and AstraZeneca (AZN +0.00%) hooked up to develop early stage BACE inhibitor AZD3293, while the New York state attorney general sued Actavis (ACT +0.00%) over its plans to pull a version of an already approved Alzheimer's drug, Namenda, off the market.
In the last piece of news, American's are getting fat(ter) around the waist. No big surprise there; the big question is whether drugs to treat obesity will ever take off.
The guys wrap up with three top picks in healthcare. Michael likes Amgen (AMGN +0.46%) for its late-stage pipeline. Brian goes smaller, suggesting investors look at Isis Pharmaceuticals (ISIS +2.13%) for its massive pipeline of next-generation antisense drugs. And David wraps up with his pick of Biogen Idec (BIIB +0.82%) for its franchise of multiple sclerosis drugs, among others.
